感染性休克 ICU 患者限制静脉输液
这项国际随机试验纳入 ICU 内感染性休克且已接受至少 1 升静脉输液、休克起病在筛查前 12 小时内的患者,比较限制性静脉输液与标准静脉输液。共纳入 1554 例(限制组 770 例,标准组 784 例),主要终点 90 天全因死亡在限制组为 42.3%(323/764),标准组为 42.1%(329/781),调整后绝对差 0.1 个百分点(95%CI -4.7 至 4.9;P=0.96)。ICU 内严重不良事件限制组 29.4%(221/751) vs 标准组 30.8%(238/772),调整后绝对差 -1.7 个百分点(99%CI -7.7 至 4.3)。90 天无生命支持存活天数及出院存活天数两组相似。
要点
- 感染性休克 ICU 患者限制静脉输液与标准输液 90 天病死率无显著差异:限制组 42.3% vs 标准组 42.1%,调整后绝对差 0.1 个百分点(95%CI -4.7 至 4.9;P=0.96)。
- ICU 内静脉输液量:限制组中位数 1798 ml(四分位距 500 至 4366),标准组中位数 3811 ml(四分位距 1861 至 6762)。
- ICU 内严重不良事件至少一次:限制组 29.4%(221/751) vs 标准组 30.8%(238/772),调整后绝对差 -1.7 个百分点(99%CI -7.7 至 4.3)。
- 90 天无生命支持存活天数及出院存活天数两组相似。
- 纳入标准为 ICU 内感染性休克、已接受至少 1 升静脉输液且休克起病在筛查前 12 小时内。
适用人群与场景
- ICU 内感染性休克成人患者,已接受至少 1 升静脉输液,且休克起病在筛查前 12 小时内。
处置流程与药物剂量
- 限制性静脉输液组在 ICU 内接受中位数 1798 ml 静脉输液(四分位距 500 至 4366)。
- 标准静脉输液组在 ICU 内接受中位数 3811 ml 静脉输液(四分位距 1861 至 6762)。
研究设计与关键结果
- 国际随机试验纳入 1554 例感染性休克 ICU 患者,限制性输液组 770 例,标准输液组 784 例;主要终点数据可获取 1545 例(99.4%)。
- 主要终点 90 天全因死亡:限制组 323/764(42.3%) vs 标准组 329/781(42.1%),调整后绝对差 0.1 个百分点(95%CI -4.7 至 4.9;P=0.96)。
- ICU 内严重不良事件至少一次:限制组 221/751(29.4%) vs 标准组 238/772(30.8%),调整后绝对差 -1.7 个百分点(99%CI -7.7 至 4.3)。
- 90 天无生命支持存活天数及出院存活天数两组相似。
证据类型、等级与局限
- 证据类型:国际随机对照试验(CLASSIC,ClinicalTrials.gov NCT03668236)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在 ICU 感染性休克成人患者中,限制性静脉输液策略与标准输液策略相比 90 天病死率无显著差异,支持不因担心液体过量而常规限制输液,也不支持常规增加输液量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous fluids are recommended for the treatment of patients who are in septic shock, but higher fluid volumes have been associated with harm in patients who are in the intensive care unit (ICU).
METHODS: In this international, randomized trial, we assigned patients with septic shock in the ICU who had received at least 1 liter of intravenous fluid to receive restricted intravenous fluid or standard intravenous fluid therapy; patients were included if the onset of shock had been within 12 hours before screening. The primary outcome was death from any cause within 90 days after randomization.
RESULTS: We enrolled 1554 patients; 770 were assigned to the restrictive-fluid group and 784 to the standard-fluid group. Primary outcome data were available for 1545 patients (99.4%). In the ICU, the restrictive-fluid group received a median of 1798 ml of intravenous fluid (interquartile range, 500 to 4366); the standard-fluid group received a median of 3811 ml (interquartile range, 1861 to 6762). At 90 days, death had occurred in 323 of 764 patients (42.3%) in the restrictive-fluid group, as compared with 329 of 781 patients (42.1%) in the standard-fluid group (adjusted absolute difference, 0.1 percentage points; 95% confidence interval [CI], -4.7 to 4.9; P = 0.96). In the ICU, serious adverse events occurred at least once in 221 of 751 patients (29.4%) in the restrictive-fluid group and in 238 of 772 patients (30.8%) in the standard-fluid group (adjusted absolute difference, -1.7 percentage points; 99% CI, -7.7 to 4.3). At 90 days after randomization, the numbers of days alive without life support and days alive and out of the hospital were similar in the two groups.
CONCLUSIONS: Among adult patients with septic shock in the ICU, intravenous fluid restriction did not result in fewer deaths at 90 days than standard intravenous fluid therapy. (Funded by the Novo Nordisk Foundation and others; CLASSIC ClinicalTrials.gov number, NCT03668236.).
参考来源
- Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med. 2022. PMID: 35709019. doi:10.1056/NEJMoa2202707
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。